XERS Filings — Xeris Biopharma Holdings, Inc. - FilingSpy
XERS
Xeris Biopharma Holdings, Inc.
A Chicago-based biopharmaceutical company that turns hard-to-inject medicines into stable, ready-to-use shots. Its brands include Gvoke, a liquid glucagon that treats dangerously low blood sugar in people with diabetes, plus Keveyis and Recorlev for rare conditions. Founded in 2005, its name comes from the Greek word for "dry," reflecting its water-free (non-aqueous) formulation technology that keeps drugs stable without the fuss of mixing before use.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -82.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.